Skip to main content
. Author manuscript; available in PMC: 2013 May 22.
Published in final edited form as: Clin Cancer Res. 2012 Mar 16;18(9):2423–2428. doi: 10.1158/1078-0432.CCR-11-1409

Figure 1.

Figure 1

Targeted therapy in neuroblastoma: Current approaches to targeted therapy for neuroblastoma involve several modalities including 1. small molecular inhibitors of activated signaling pathways (ALK, IGF1R, MEK, PLK1, AURKA, PI3K and mTOR inhibitors) 2. radiopharmaceuticals targeting the NET receptor (131I-MIBG, 211At-MABG) and 3. immunotherapy (anti-GD2 antibodies).